ACTRIS signs MOU with Cell Therapies

We are pleased to announce that we have signed a Memorandum of Understanding (MoU) with Cell Therapies Pty Ltd, Australia’s Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapies (CGT).

This MoU marks the first step in a strategic collaboration aimed at accelerating ACTRIS’ operational readiness to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. By combining our state-of-the-art GMP infrastructure and vision to be a regional Centre of Excellence with Cell Therapies’ decades of experience in CGT development, clinical translation, and commercial manufacturing, we aim to expand patient access to advanced therapies across Singapore and the Asia Pacific region.

Together, we will optimise GMP-compliant manufacturing processes, enable efficient technology transfer and scale-up, strengthen regulatory strategies, and build long-term workforce and infrastructure capabilities. This collaboration also reflects Cell Therapies’ commitment to its Asia Pacific Alliance Model (APAM), supporting a coordinated pathway for global sponsors advancing CGT programmes across the region.

We look forward to deepening this collaboration as we jointly contribute to a robust, sustainable, and innovation-driven CGT ecosystem in Asia-Pacific.